Vadim Markovtsov

Vadim Markovtsov

Company: Rigel Pharmaceuticals

Job title: Executive Director, Translational Biology


Phenocopying IRAK1/4 Inhibition With R289 and Its Translation Into The Clinic Using a prodrug of R835 to inhibit IRAK1/4: R289 5:00 pm

Selectively inhibiting inflammatory innate immune signalling to tissue damage signals (PAMPs/DAMPs/IL-1 family of cytokines) in cells, animals and whole blood assays Profoundly inhibiting inflammatory cytokine production induced by i.v. dosed LPS in healthy volunteers with R835 Phase 1 results position R289 attractively with respect to its translational PK/PD dataRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.